Autolus Shows Long Responses To CD19 CAR-T Therapy In Adult ALL Patients

Responses Longest With Low To Intermediate Tumor Burden

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.